3000 ( 25 )
14 In addition, any product candidates that we successfully develop and commercialize, including those from our PTH1R program and SEP-631, may compete with existing therapies and new therapies that may become available in the future that are approved to treat the same diseases for which we may obtain approval for our product candidates
Short Answer: DSIP remains an experimental peptide with limited evidence for sleep and insufficient evidence for most recovery, hormone, stress, bodybuilding, and brain-health claims
Her attitude and professionalism were impeccable, making the entire process seamless and enjoyable
AGEN2034 / EP4 + PD-1 / EP4 antagonist plus PD-1 antagonist / OncologypMMR-MSS colorectal cancerPhase 1/2Ongoing NLM001 + ZalifrelimabNLM-001 / Hedgehog + CTLA-4 / Hedgehog inhibitor plus CTLA-4 antagonist / OncologyAdvanced pancreatic cancerPhase 1/2Ongoing OBT076 + BalstilimabOBT076
This effect on CKD progression persisted across all subgroups, although there was some heterogeneity of effect based on index date